Figure 5: This algorithm is a combined interpretation of the 2010 G-CSF guidelines of European Organisation for Research and Treatment of Cancer (EORTC) and American Society of Clinical Oncology (ASCO) [8, 39]. All of these organisations recommend that the physician should use their clinical judgement to assess FN risk as greater or less than 20% according to the estimated risk of expected neutropenic complications, based on the treatment regimen and patient-specific characteristics, including age ≥65 years and experience of FN in a previous chemotherapy cycle.